Incannex Healthcare (NASDAQ:IXHL – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.51, FiscalAI reports.
Incannex Healthcare Price Performance
NASDAQ:IXHL traded up $0.04 during mid-day trading on Thursday, reaching $2.02. The stock had a trading volume of 103,777 shares, compared to its average volume of 80,369. The business’s 50 day moving average is $2.95 and its 200 day moving average is $3.88. Incannex Healthcare has a fifty-two week low of $1.96 and a fifty-two week high of $14.91. The stock has a market cap of $25.35 million, a P/E ratio of -1.19 and a beta of 7.00.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on IXHL. Zacks Research lowered shares of Incannex Healthcare from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Incannex Healthcare in a report on Thursday, October 15th. Finally, Wall Street Zen cut Incannex Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, October 3rd. One equities research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $18.00.
View Our Latest Analysis on IXHL
Incannex Healthcare Company Profile
Incannex Healthcare Limited (NASDAQ: IXHL) is an Australia-based clinical-stage pharmaceutical company developing cannabinoid- and psychedelic-assisted therapies for conditions with significant unmet medical needs. The company’s research programs are focused on areas including sleep disorders, pain, inflammation, mental health and traumatic brain injury. Incannex’s lead programs have included IHL-42X, an investigational combination therapy being developed for obstructive sleep apnea, and IHL-675A, a cannabinoid-based therapy studied for inflammatory conditions.
Featured Stories
- Five stocks we like better than Incannex Healthcare
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
